Brand name authorized in: Ireland Lithuania Poland United Kingdom
The drug ADTRALZA contains one active pharmaceutical ingredient (API):
Tralokinumab is a fully human IgG4 monoclonal antibody that specifically binds to the type 2 cytokine interleukin-13 (IL-13) and inhibits its interaction with the IL-13 receptors. IL-13 is a major driver of human type 2 inflammatory disease, such as atopic dermatitis and inhibiting the IL-13 pathway with tralokinumab in patients decreases many of the mediators of type 2 inflammation.
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
Below package inserts are available for further reading:
This drug has been assigned below unique identifiers within the countries it is being marketed: